INS and type 2 diabetes mellitus: Sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) represent a new class of anti-hyperglycemic agents for T2DM, which act as insulin independent to selectively inhibit renal glucose reabsorption, thereby increasing urinary glucose excretion.